DNA based neoepitope vaccination induces tumor control in syngeneic mouse models
Abstract Recent findings have positioned tumor mutation-derived neoepitopes as attractive targets for cancer immunotherapy. Cancer vaccines that deliver neoepitopes via various vaccine formulations have demonstrated promising preliminary results in patients and animal models. In the presented work,...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-05-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-023-00671-5 |
| _version_ | 1797426898950684672 |
|---|---|
| author | Nadia Viborg Michail Angelos Pavlidis Marina Barrio-Calvo Stine Friis Thomas Trolle Anders Bundgaard Sørensen Christian Bahne Thygesen Søren Vester Kofoed Daniela Kleine-Kohlbrecher Sine Reker Hadrup Birgitte Rønø |
| author_facet | Nadia Viborg Michail Angelos Pavlidis Marina Barrio-Calvo Stine Friis Thomas Trolle Anders Bundgaard Sørensen Christian Bahne Thygesen Søren Vester Kofoed Daniela Kleine-Kohlbrecher Sine Reker Hadrup Birgitte Rønø |
| author_sort | Nadia Viborg |
| collection | DOAJ |
| description | Abstract Recent findings have positioned tumor mutation-derived neoepitopes as attractive targets for cancer immunotherapy. Cancer vaccines that deliver neoepitopes via various vaccine formulations have demonstrated promising preliminary results in patients and animal models. In the presented work, we assessed the ability of plasmid DNA to confer neoepitope immunogenicity and anti-tumor effect in two murine syngeneic cancer models. We demonstrated that neoepitope DNA vaccination led to anti-tumor immunity in the CT26 and B16F10 tumor models, with the long-lasting presence of neoepitope-specific T-cell responses in blood, spleen, and tumors after immunization. We further observed that engagement of both the CD4+ and CD8+ T cell compartments was essential to hamper tumor growth. Additionally, combination therapy with immune checkpoint inhibition provided an additive effect, superior to either monotherapy. DNA vaccination offers a versatile platform that allows the encoding of multiple neoepitopes in a single formulation and is thus a feasible strategy for personalized immunotherapy via neoepitope vaccination. |
| first_indexed | 2024-03-09T08:36:31Z |
| format | Article |
| id | doaj.art-018569528672479ca528c27630e5b5be |
| institution | Directory Open Access Journal |
| issn | 2059-0105 |
| language | English |
| last_indexed | 2024-03-09T08:36:31Z |
| publishDate | 2023-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj.art-018569528672479ca528c27630e5b5be2023-12-02T18:01:26ZengNature Portfolionpj Vaccines2059-01052023-05-018111610.1038/s41541-023-00671-5DNA based neoepitope vaccination induces tumor control in syngeneic mouse modelsNadia Viborg0Michail Angelos Pavlidis1Marina Barrio-Calvo2Stine Friis3Thomas Trolle4Anders Bundgaard Sørensen5Christian Bahne Thygesen6Søren Vester Kofoed7Daniela Kleine-Kohlbrecher8Sine Reker Hadrup9Birgitte Rønø10Evaxion BiotechEvaxion BiotechEvaxion BiotechEvaxion BiotechEvaxion BiotechEvaxion BiotechEvaxion BiotechEvaxion BiotechEvaxion BiotechDepartment of Health Technology, Technical University of DenmarkEvaxion BiotechAbstract Recent findings have positioned tumor mutation-derived neoepitopes as attractive targets for cancer immunotherapy. Cancer vaccines that deliver neoepitopes via various vaccine formulations have demonstrated promising preliminary results in patients and animal models. In the presented work, we assessed the ability of plasmid DNA to confer neoepitope immunogenicity and anti-tumor effect in two murine syngeneic cancer models. We demonstrated that neoepitope DNA vaccination led to anti-tumor immunity in the CT26 and B16F10 tumor models, with the long-lasting presence of neoepitope-specific T-cell responses in blood, spleen, and tumors after immunization. We further observed that engagement of both the CD4+ and CD8+ T cell compartments was essential to hamper tumor growth. Additionally, combination therapy with immune checkpoint inhibition provided an additive effect, superior to either monotherapy. DNA vaccination offers a versatile platform that allows the encoding of multiple neoepitopes in a single formulation and is thus a feasible strategy for personalized immunotherapy via neoepitope vaccination.https://doi.org/10.1038/s41541-023-00671-5 |
| spellingShingle | Nadia Viborg Michail Angelos Pavlidis Marina Barrio-Calvo Stine Friis Thomas Trolle Anders Bundgaard Sørensen Christian Bahne Thygesen Søren Vester Kofoed Daniela Kleine-Kohlbrecher Sine Reker Hadrup Birgitte Rønø DNA based neoepitope vaccination induces tumor control in syngeneic mouse models npj Vaccines |
| title | DNA based neoepitope vaccination induces tumor control in syngeneic mouse models |
| title_full | DNA based neoepitope vaccination induces tumor control in syngeneic mouse models |
| title_fullStr | DNA based neoepitope vaccination induces tumor control in syngeneic mouse models |
| title_full_unstemmed | DNA based neoepitope vaccination induces tumor control in syngeneic mouse models |
| title_short | DNA based neoepitope vaccination induces tumor control in syngeneic mouse models |
| title_sort | dna based neoepitope vaccination induces tumor control in syngeneic mouse models |
| url | https://doi.org/10.1038/s41541-023-00671-5 |
| work_keys_str_mv | AT nadiaviborg dnabasedneoepitopevaccinationinducestumorcontrolinsyngeneicmousemodels AT michailangelospavlidis dnabasedneoepitopevaccinationinducestumorcontrolinsyngeneicmousemodels AT marinabarriocalvo dnabasedneoepitopevaccinationinducestumorcontrolinsyngeneicmousemodels AT stinefriis dnabasedneoepitopevaccinationinducestumorcontrolinsyngeneicmousemodels AT thomastrolle dnabasedneoepitopevaccinationinducestumorcontrolinsyngeneicmousemodels AT andersbundgaardsørensen dnabasedneoepitopevaccinationinducestumorcontrolinsyngeneicmousemodels AT christianbahnethygesen dnabasedneoepitopevaccinationinducestumorcontrolinsyngeneicmousemodels AT sørenvesterkofoed dnabasedneoepitopevaccinationinducestumorcontrolinsyngeneicmousemodels AT danielakleinekohlbrecher dnabasedneoepitopevaccinationinducestumorcontrolinsyngeneicmousemodels AT sinerekerhadrup dnabasedneoepitopevaccinationinducestumorcontrolinsyngeneicmousemodels AT birgitterønø dnabasedneoepitopevaccinationinducestumorcontrolinsyngeneicmousemodels |